Please login to the form below

Not currently logged in
Email:
Password:

Dr Julian Howell joins Shield Therapeutics as group medical director

Mineral medicines company also appoints Dr Lynn Drummond to the board

Shield Therapeutics medical director Dr Julian HowellUK mineral medicines company Shield Therapeutics has appointed Dr Julian Howell as group medical director and VP of drug development.

He joins the specialty pharma company after spending six years at ProStrakan, where he led its clinical development and drug safety group.

Dr Howell spent six years in the NHS, gaining medical and surgical qualifications, and began his industry career with SmithKline Beecham and then at Roche, before moving to smaller companies.

Dr Howell said: “I am very pleased to be joining the team at Shield … I look forward to adding my clinical development experience and medical knowledge to the skilled team already in place to help ensure that our products become available as quickly and safely as possible to patients with such clear unmet medical needs.”

Shield Therapeutics has also appointed Dr Lynn Drummond to its board as a non-executive director.

She has over 25 years of management and advisory experience, spending 16 years at Rothschild in London, most recently as a managing director within the investment banking division, with a particular focus on transactions within the healthcare sector.

13th May 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics